Literature DB >> 26622745

Primary cerebellopontine angle ependymoma with spinal metastasis in an adult patient: A case report.

Chengcheng Zhao1, Chuanfang Wang2, Meng Zhang3, Taipeng Jiang3, Wenlan Liu4, Weiping Li3.   

Abstract

Subtentorial ependymoma is a common central nervous system tumor in young children, but is uncommon in adults. Ependymoma often arises from the cells lining the fourth ventricle. The present study reports a rare case of primary ependymoma that originated from the cerebellopontine angle, with local extension to the two internal auditory canals and remote spinal metastasis, in an adult male. A 50-year-old male presented with headache, tinnitus and bilateral hearing loss that had persisted for 4 months. Magnetic resonance imaging (MRI) revealed a mass in each of the cerebellopontine angles, which had spread to each internal auditory canal and wrapped the VII/VIII cranial nerve complex. A gross total resection was performed to remove the mass in the right side. Histological examination confirmed that the tumor was a World Health Organization grade II papillary ependymoma. Notably, the patient complained of urine retention post-surgery and massive occupational lesions in T3-T4 and L5-S2 were found on full spinal cord MRI. The patient then received combination therapy consisting of temozolomide, and whole-brain and spinal cord radiation. In the final follow-up examination, performed 13 months after treatment, slight shrinkage of the T3 lesion was observed, and no progression of the left cerebellopontine angle and S5-L2 lesions were identified on MRI. In summary, although this clinical entity is rare, the diagnosis of ependymoma and the possibility of spinal cord metastasis should be considered in subtentorial tumors.

Entities:  

Keywords:  cerebellopontine angle; ependymoma; spinal metastasis

Year:  2015        PMID: 26622745      PMCID: PMC4533608          DOI: 10.3892/ol.2015.3409

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.

Authors:  C F Freyschlag; J Tuettenberg; F Lohr; C Thomé; K Schmieder; M Seiz
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

2.  [Malnutrition as a multiple cause of death].

Authors:  P Bustamante-Montes; A R Villa-Romero; M A Lezana-Fernández; R Fernández de Hoyos; V H Borja-Aburto; A Lona-Zamora; R A Rascón-Pacheco
Journal:  Salud Publica Mex       Date:  1991 Sep-Oct

Review 3.  Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation.

Authors:  E Bouffet; G Perilongo; A Canete; M Massimino
Journal:  Med Pediatr Oncol       Date:  1998-06

4.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.

Authors:  Philippe Metellus; Jacques Guyotat; Olivier Chinot; Anne Durand; Marylin Barrie; Roch Giorgi; Anne Jouvet; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2010-05-19       Impact factor: 12.300

Review 5.  Ependymoma: new therapeutic approaches including radiation and chemotherapy.

Authors:  Thomas E Merchant; Maryam Fouladi
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

6.  Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas.

Authors:  Michael C Oh; Michael E Ivan; Matthew Z Sun; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Eli T Sayegh; Derick Aranda; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-12-09       Impact factor: 12.300

7.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

8.  Ependymoma in adults: surgery, reoperation and radiotherapy for survival.

Authors:  Dusan Vitanovics; Katalin Bálint; Zoltán Hanzély; Péter Banczerowski; Dénes Afra
Journal:  Pathol Oncol Res       Date:  2009-08-30       Impact factor: 3.201

9.  Images in neuro oncology: primary extraaxial cerebellopontine angle ependymoma.

Authors:  Manish K Kasliwal; P Sarat Chandra; Bhawani Shanker Sharma
Journal:  J Neurooncol       Date:  2007-03-30       Impact factor: 4.506

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  6 in total

1.  Cerebellopontine angle ependymoma presenting as isolated hearing loss in an elderly patient: A case report and literature review.

Authors:  Khaled Dibs; Rahul Neal Prasad; Kajal Madan; Kevin Liu; Will Jiang; Jayeeta Ghose; Dukagjin M Blakaj; Joshua D Palmer; Peter Kobalka; Daniel M Prevedello; Raju R Raval
Journal:  Surg Neurol Int       Date:  2021-11-23

Review 2.  No Laughing Matter: Gelastic Migraine and Other Unusual Headache Syndromes.

Authors:  Paul G Mathew; Carrie E Robertson
Journal:  Curr Pain Headache Rep       Date:  2016-05

3.  Cerebellopontine angle ependymoma in a young adult: A case report.

Authors:  Zhigang Lan; Seidu A Richard; Yuekang Zhang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

4.  Case report: Primary ependymoma of the trigeminal nerve presenting as trigeminal neuralgia.

Authors:  Zara Shah; Mohammad Yousuf Islam; Fatima Suleman; Aisha Hassan Memon; Fatima Mubarak; Shahzad M Shamim
Journal:  Surg Neurol Int       Date:  2022-08-19

5.  Ependymoma in supratentorial extra-axial location.

Authors:  Abdulrahman Y Alturki; Nasir R Awan; Khaled N Almusrea
Journal:  Neurosciences (Riyadh)       Date:  2016-04       Impact factor: 0.906

6.  Simultaneous cerebrospinal fluid and hematologic metastases in a high-grade ependymoma.

Authors:  Daniel Diaz-Aguilar; Sergei Terterov; Alexander M Tucker; Shaina Sedighim; Rudi Scharnweber; Stephanie Wang; Catherine Merna; Shayan Rahman
Journal:  Surg Neurol Int       Date:  2018-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.